XCath has announced that it presented at the recent Stroke Live Course (SLICE) Next Frontiers conference (3–4 April, virtual), hosted by Vincent Costalat (University Hospital of Montpellier, Montpellier, France), and Master and Fellow.
The event—broadcast live from the Montpellier Centre Hospitalier Universitaire in Montpellier, France—was designed to address the endovascular treatment of cerebral pathologies.
XCath’s chief executive officer, Eduardo Fonseca, gave a presentation titled, “The future of endovascular interventions”, focusing on the process behind endovascular robotic procedures, and XCath’s efforts to develop devices that could potentially deliver practical, clinical and commercial value beyond the lab.
Vitor Pereira (St Michael’s Hospital, Toronto, Canada) and Adnan Siddiqui (University of Buffalo, Buffalo, USA) were also present, and—as per an XCath press release—provided a “very positive view” on robotics, agreeing that it is a burgeoning field and that the future of neurovascular interventions will include the technology.
“The SLICE Next Frontiers conference convenes thought leaders from across the neuro space, and is a key opportunity to learn about current innovations and where we’re going next,” said Fonseca. “In conversations that took place at the event about robotics, AI [artificial intelligence] and telerobotics, there was a lot of enthusiasm about how these technologies can enhance patient care. These objectives are all top of mind at XCath, and we look forward to being part of the future of neurovascular interventions.”
In the release, XCath describes itself as an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and steerable guidewires.
